Sequence variant classification and reporting: recommendations for improving the interpretation of cancer susceptibility genetic test results
Sharon E. Plon, Diana Eccles, Douglas F. Easton et al. · Human Mutation · 2008
Genetic testing of cancer susceptibility genes is now widely applied in clinical practice to predict risk of developing cancer. In general, sequence-based testing of germline DNA is used to determine whether an individual carries a change that is clearly likely to disrupt normal gene function. Genetic testing may detect changes that are clearly pathogenic, clearly neutral, or variants of unclear clinical significance. Such variants present a considerable challenge to the diagnostic laboratory and the receiving clinician in terms of interpretation and clear presentation of the implications of the result to the patient. There does not appear to be a consistent approach to interpreting and reporting the clinical significance of variants either among genes or among laboratories. The potential for confusion among clinicians and patients is considerable and misinterpretation may lead to inappropriate clinical consequences. In this article we review the current state of sequence-based genetic testing, describe other standardized reporting systems used in oncology, and propose a standardized classification system for application to sequence-based results for cancer predisposition genes. We suggest a system of five classes of variants based on the degree of likelihood of pathogenicity. Each class is associated with specific recommendations for clinical management of at-risk relatives that will depend on the syndrome. We propose that panels of experts on each cancer predisposition syndrome facilitate the classification scheme and designate appropriate surveillance and cancer management guidelines. The international adoption of a standardized reporting system should improve the clinical utility of sequence-based genetic tests to predict cancer risk.
Cited by 911 works. doi:10.1002/humu.20880 Open-access PDF
Authors
- Sharon E. Plon
- Diana Eccles
- Douglas F. Easton
- William David Foulkes
- Maurizio Genuardi
- Marc S. Greenblatt
- Frans B.L. Hogervorst
- Nicoline Hoogerbrugge
- Amanda B. Spurdle
- Sean V. Tavtigian
- Georgia Chenevix‐Trench
References
- Genome-wide association study identifies novel breast cancer susceptibility loci
- ACMG recommendations for standards for interpretation and reporting of sequence variations: Revisions 2007
- A genome-wide association study identifies alleles in FGFR2 associated with risk of sporadic postmenopausal breast cancer
- Mutations and Polymorphisms in the familial early-onset breast cancer (BRCA1) gene
- Clinical Characteristics of Individuals With Germline Mutations in BRCA1 and BRCA2: Analysis of 10,000 Individuals
- Integrated Evaluation of DNA Sequence Variants of Unknown Clinical Significance: Application to BRCA1 and BRCA2
- Clinical Characteristics of Individuals With Germline Mutations in BRCA1 and BRCA2 : Analysis of 10,000 Individuals
- Risk of Perforation After Colonoscopy and Sigmoidoscopy: A Population-Based Study
- Variability and Accuracy in Mammographic Interpretation Using the American College of Radiology Breast Imaging Reporting and Data System
- A Systematic Genetic Assessment of 1,433 Sequence Variants of Unknown Clinical Significance in the BRCA1 and BRCA2 Breast Cancer–Predisposition Genes